VIDEO – Take a look at the U.S. government’s response in addressing Ebola in the United States.
Watch a video and take a look at the U.S. government’s response in addressing Ebola in the United States.
Pharmaceuticals, Biotechnology and Life Sciences
Watch a video and take a look at the U.S. government’s response in addressing Ebola in the United States.
Teva Pharmaceutical Industries Ltd. has announced that it has entered into definitive agreements under which the Company will acquire Representaciones e Investigaciones Médicas, S.A. de C.V. (Rimsa), a pharmaceutical manufacturing and distribution company in Mexico
The U.S. Food and Drug Administration ordered on Monday the three manufacturers of duodenoscopes marketed in the U.S. to conduct postmarket surveillance studies to better understand how the devices are reprocessed in real-world settings.
Johnson & Johnson has completed the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion.
The Nobel Assembly at Karolinska Institutet has today decided to award the 2015 Nobel Prize in Physiology or Medicine with one half jointly to William C. Campbell and Satoshi Ōmura for their discoveries concerning a novel therapy against infections caused by roundworm parasites and the other half to Youyou Tu for her discoveries concerning a novel therapy against Malaria.
William C. Campbell and Satoshi Ōmura split Nobel prize in Physiology or Medicine 2015 with Youyou Tu, for discoveries regarding novel therapies for some of the most devastating parasitic diseases.
Roche’s new HbA1c testing solution, the cobas c 513 analyser, is now available for countries accepting the CE mark,
Premaitha Health has signed a distribution agreement with Antisel SA, a Greek distributor of scientific products, to provide the IONA test to clinical laboratories in the region.
Allergan plc, has announced a multi-year research collaboration with Humana Inc. to explore new ideas and ways to improve the health and well-being of patients, members and their caregivers.
Sanofi and its subsidiary Genzyme have announced that Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialization in territories outside of North America and Western Europe.